glutathione synthesis cofactors Glutathione-Dependent Pathways in Cancer Cells Glutathione: A powerful but rare

VIDA 5.0.3: OpenEye Scientific Software SF, NM

D.LewisJ

If target IOP is not achieved in a compliant patient, substitution or addition of newer medications can be considered. Real- world studies have shown both latanoprostene bunod and netarsudil to provide additional IOP reductions in patients already taking three or more medications

doi: 10.3389/fphar.2019.00250 Received 24 October 2018 Accepted 26 February 2019 Published 20 March 2019 Volume 10 - 2019 Edited by Annette Nicke, Ludwig Maximilian University of Munich, Germany Reviewed by Hai Minh Nguyen, University of California, Davis, United States

& Price, S

Powell-Wiley TM, Poirier P, Burke LE, Desprs JP, Gordon-Larsen P, Lavie CJ, et al